Study on the Treatment of Dental Implants Using the AmbiJet System for Peri-implantitis and Peri-implant Mucositis

Inclusion Criteria: General criteria: * Men or women aged \>= 18 and \<= 65 years. * For women of childbearing age: a form of contraception recognized by conventional medicine during the study. * Written consent has been obtained from each patient for the study. Dental criteria: * Current X-ray of the implant region available (\<= 6 months prior to first treatment). * One to five implants with bone loss from the start of the part of the implant intended for osseointegration (X-ray findings). * Bleeding and/or suppuration after or without probing at the implant in question (peri-implant mucositis/peri-implantitis). * Clinical signs of inflammation (swelling, redness, soft tissue) on the implant in question (peri-implant mucositis/peri-implantitis). * Average oral hygiene (i.e., brushing teeth at least twice a day). Exclusion Criteria: General criteria: * Known allergies to materials used in the study (gold, copper, polyimide). * Diabetes (type I or type II), vasculitis, osteoporosis, osteomalacia. * Smokers (\>1 cigarette/week). * Use of medications to modulate bone metabolism (e.g., bisphosphonates). * Eating disorders such as bulimia or anorexia nervosa. * Use of antibiotics within the last 2 months prior to the start of the study. * Application of local antibiotics in the oral cavity within the last 2 months prior to the start of the study. * Use of antimicrobial mouthwashes within the last month before the start of the study. * Anti-inflammatory medication within the last month before the start of the study. * Pregnancy or breastfeeding. * Alcoholism or drug abuse. * Wound healing disorders. * Immunosuppression. * Condition following insertion of an electrical, electrically active, or electronic implant. Dental criteria: * An implant with bone loss \>6 mm from the start of the part of the implant intended for osseointegration (X-ray findings) (peri-implantitis). * Pathological changes in the oral mucosa or gingiva, such as oral lichen planus, chronic recurrent aphthae, melanotic macula, precancerous lesions (e.g., leukoplakia), melanomas. * Use of medically unacceptable types of treatment, therapies, or substances (off-label use of treatments for peri-implant mucositis or peri-implantitis).